Boehringer Ingelheim

Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

More... »

Coldstream Laboratories names VP of manufacturing

Tuesday, November 22, 2011 01:37 PM

Coldstream Laboratories, a provider of drug product research and manufacturing services, has named Dr. Vickie Hall vice president of manufacturing. Hall will assume responsibility of Coldstream's manufacturing, facilities, and warehouse operations.

More... »

FDA approves Combivent Respimat for COPD

Tuesday, October 11, 2011 12:11 PM

Boehringer Ingelheim Pharmaceuticals has reported that the FDA has approved COMBIVENT RESPIMAT, a new, propellant-free inhaler product that uses a slow-moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler (COMBIVENT MDI). COMBIVENT RESPIMAT will be available for patients in mid-2012.

More... »

Boehringer Ingelheim creates biosmiliars division

Tuesday, September 27, 2011 01:36 PM

Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that market, according to InPharm.

More... »

Nuevolution, Boehringer collaborate in drug discovery

Tuesday, September 20, 2011 12:22 PM

Nuevolution has entered into a collaboration with Boehringer Ingelheim, using Nuevolution’s proprietary Chemetics drug discovery technology.

More... »

Lilly expects original drugs sales to triple in India

Friday, September 16, 2011 11:15 AM

American drug maker Eli Lilly will bet on its original drugs as it aims to triple sales in India over the next five years. Unlike other foreign drug makers, it plans to stay away from acquisition of local firms or branded generics to boost its market share, according to The Economic Times.

More... »

Boehringer builds $42.5 million R&D facility

Thursday, August 25, 2011 10:57 AM

Boehringer Ingelheim Pharmaceuticals, broke ground on a new $42.5-million safety assessment building to be built over the next two years on its 294-acre campus in Ridgefield and Danbury, according to the Ridgefield Press.

More... »

Boehringer/Lilly's diabetes drug receives FDA approval

Tuesday, May 3, 2011 12:20 PM

Boehringer Ingelheim and its partner Eli Lilly report that the FDA has approved their once-daily type II diabetes pill linagliptin (Tradjenta).

More... »

Boehringer enrolls first patient in phase III trial for HVC

Wednesday, April 27, 2011 12:09 PM

Boehringer Ingelheim Pharmaceuticals has begun enrollment at North American sites in its phase III clinical trial program for BI 201335, the company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV). Phase III trials have begun recruiting to evaluate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1 HCV, the most challenging HCV genotype to treat.

More... »

Boehringer finalizes Amgen acquisition

Tuesday, March 29, 2011 10:25 AM

Boehringer has formally acquired Amgen's biopharmaceutical development and manufacturing facility in Fremont, Calif.

More... »